Establishment and characterization of a murine model for allergic asthma using allergen-specific IgE monoclonal antibody to study pathological roles of IgE.
Allergen-specific IgE has long been regarded as a major molecular component of allergic asthma. Although IgE plays a central role in the early asthmatic response, its roles in the chronic phase, such as the late asthmatic response, airway hyperresponsiveness (AHR), and airway remodeling (goblet cell hyperplasia and subepithelial fibrosis) have not yet been defined well. In this study, we investigated the hypothesis that chronic responses could be induced by IgE-dependent mechanisms. BALB/c mice passively sensitized with an ovalbumin (OVA)-specific IgE monoclonal antibody (mAb) were repeatedly challenged with intratracheal administration of OVA. The first challenge induced early phase airway narrowing without any late response, but the fourth challenge caused not only an early but also a late phase response, AHR, and goblet cell hyperplasia. Macrophages, lymphocytes and neutrophils, but not eosinophils, were significantly increased in the lung 24h after the fourth challenge. Interestingly, levels of OVA-specific IgG1 in serum increased by multiple antigen challenges. A C3a receptor antagonist inhibited the late asthmatic response, AHR, and infiltration by neutrophils. In contrast, no late response, goblet cell hyperplasia, inflammatory cells, or production of IgG1 was observed in severe combined immunodeficient mice. On the other hand, seven challenges in BALB/c mice induced subepithelial fibrosis associated with infiltration by eosinophils. In conclusion, the allergic asthmatic responses induced by passive sensitization with IgE mAb can provide a useful model system to study the pathological roles of IgE in acute and chronic phases of allergic asthma.
Department of Pharmacology, Kobe Pharmaceutical University, 4-19-1 Motoyamakita, Higashinada, Kobe 658-8558, Japan. mizutani@kobepharma-u.ac.jp
Nobuaki
N
Mizutani
Hirofumi
H
Goshima
Takeshi
T
Nabe
Shin
S
Yoshino
D000485:Allergens / Q000276:immunology; D000818:Animals; D000936:Antigen-Antibody Complex / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology; D001120:Arginine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D001249:Asthma / Q000139:chemically induced / Q000276:immunology* / Q000503:physiopathology; D001559:Benzhydryl Compounds / Q000008:administration & dosage / Q000009:adverse effects; D016535:Bronchial Hyperreactivity; D002465:Cell Movement / Q000187:drug effects / Q000276:immunology; D002908:Chronic Disease; D004195:Disease Models, Animal; D020397:Goblet Cells / Q000473:pathology; D006801:Humans; D006965:Hyperplasia; D007114:Immunization; D007073:Immunoglobulin E / Q000276:immunology / Q000378:metabolism*; D007074:Immunoglobulin G / Q000097:blood; D051379:Mice; D008807:Mice, Inbred BALB C; D009504:Neutrophils / Q000187:drug effects / Q000473:pathology; D010047:Ovalbumin / Q000276:immunology / Q000378:metabolism*; D011951:Receptors, Complement / Q000037:antagonists & inhibitors
D000485:Allergens; D000936:Antigen-Antibody Complex; D001559:Benzhydryl Compounds; D007074:Immunoglobulin G; D011951:Receptors, Complement; C431907:SB 290157; D007073:Immunoglobulin E; D010047:Ovalbumin; D001120:Arginine